-
10.15.2024 | Super batteri, la nuova pandemia è già qui: parte la caccia ai nuovi antibiotici
IL SOLE 24 ORE | Già oggi provoca 11mila morti l'anno soltanto in Italia. Secondo l'Oms diventerà la prima causa di morte nel 2050.
-
10.11.2024 | Il piano italiano contro l’antibiotico resistenza: “Nel 2050 sarà la prima causa di morte”
LA STAMPA | Un po' per l'uso smodato che se ne fa, in parte perche negli ospedali non si presta ancora l'attenzione necessaria a prevenire le infezioni e in misura non e inferiore per il fatto che l'industria ha smesso di fare ricerca sui nuovi antibiotic.
-
10.11.2024 | G7 Salute: 21 mln di dollari per nuovi antibiotici, la mossa dell’Italia
FORTUNE ITALIA | Non prendono alla leggera la minaccia di un’Apocalisse antibiotica i ministri riuniti ad Ancona per il G7 Salute.
-
10.11.2024 | La resistenza agli antibiotici è la vera pandemia da affrontare
AVVENIRE | Il ministro Schillaci ha annunciato il piano per affrontare quella che ha definito «un'emergenza globale». il governo ha in programma assunzioni di medici e infermieri per i prossimi tre anni
-
09.30.2024 | Funding the future: Sustainable financing models to help the fight against antimicrobial resistance
FORBES | The growing problem of antimicrobial resistance, or AMR, has been called a “silent pandemic”, a “slow-motion tsunami”, and one of the “top 10 global health threats to humanity in the 21st century”.
-
09.26.2024 | Key players in the fight against antibiotic-resistant bacteria
FINTECH ZOOM | The rise of antibiotic-resistant bacteria poses a significant threat to global health, challenging the effectiveness of traditional treatments for bacterial infections. From common urinary tract infections to life-threatening conditions like cystic fibrosis, the need for innovative solutions has an impact on various medical fields.
-
09.25.2024 | It’s time to sound the alarm on superbugs
PEW CHARITABLE TRUSTS | The United Nations General Assembly’s first high-level meeting on antimicrobial resistance (AMR) in 2016 was a pivotal moment, highlighting the scope and urgency of this public health crisis.
-
09.16.2024 | Drug-resistant infections are on the rise – so why aren’t we getting any new antibiotics?
THE GUARDIAN | World leaders will meet in New York this month to discuss growing antimicrobial resistance as researchers warn the development of replacement drugs is stalling.
-
09.03.2024 | More countries are addressing AMR, but many reluctant to commit to specific cut to animal antibiotic use
HEALTH POLICY WATCH | While more countries are concerned about antimicrobial resistance (AMR) than a decade ago, many are reluctant to commit to a specific target to reduce the overuse of animal antibiotics as they negotiate a political declaration ahead of the United Nations high-level meeting on AMR.
-
09.02.2024 | Explained: the history of progress in tackling antimicrobial resistance
WELLCOME | This century has seen greater political interest in antimicrobial resistance and increased efforts to monitor, understand and treat drug-resistant infections. Is enough being done to tackle a growing global health crisis?
-
08.21.2024 | What happens when the last AMR researcher turns off the lights in the lab?
INFECTIOUS DISEASE SPECIAL EDITION | Much of modern medicine is possible because of antibiotics. Orthopedic surgeries, caesarean deliveries, and heart and kidney transplants are made safer by antibiotics.
-
07.25.2024 | House Budget Committee examines budgetary effects of antimicrobial resistance and the broken antibiotic development pipeline
HOUSE BUDGET COMMITTEE | CARB-X Executive Director Kevin Outterson joined other industry experts at a House Budget Committe bipartisan roundtable entitled “Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance and the Broken Antibiotic Development Pipeline.”
-
04.17.2024 | As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene
PHARMAVOICE | AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.
-
03.08.2024 | Professor Kevin Outterson speaks on antimicrobial resistance
TUFTS DAILY | Kevin Outterson, a professor at Boston University, bridges economics, health equity and scientific research in his discussion about how to combat antimicrobial resistance.
-
03.06.2024 | Non-profits take over from Big Pharma in new drugs trials
JUTA MEDICAL BRIEF | Effective, affordable antimicrobial drugs are desperately needed around the world, and last November, a clinical trial offered a glimmer of hope, when an oral antibiotic, called zoliflodacin, was shown to be effective against the bacterium that causes gonorrhoea.
-
03.06.2024 | CARB-X funds 100th project—a milestone for BU-based nonprofit leading antimicrobial-resistance fightback
THE BRINK | Global partnership led by BU law professor has now given $452.6 million in funding to support promising new antibiotics, vaccines, and rapid diagnostics—and is ready to support more projects.
-
03.05.2024 | With new award, CARB-X hits the 100-project mark in battling antibiotic resistance
CIDRAP | CARB-X today announced funding for its 100th project addressing antimicrobial resistance (AMR).
-
02.28.2024 | Can non-profits beat antibiotic resistance and soaring drug costs?
NATURE | Last November, a clinical trial offered a glimmer of hope in the often gloomy fight against antimicrobial resistance. An oral antibiotic, called zoliflodacin, was shown to be effective against the bacterium that causes the sexually transmitted disease gonorrhoea.
-
02.15.2024 | Could a single synthetic molecule outsmart a variety of drug-resistant bacteria?
LOS ANGELES TIMES | An estimated 2.8 million people in the U.S. contract infections each year from bacteria resistant to antibiotics, according to the U.S. Centers for Disease Control. More than 35,000 of them die.
Toggle navigation